ertapenem


Also found in: Medical, Wikipedia.
Related to ertapenem: Meropenem
Translations

ertapenem

n ertapenem m
References in periodicals archive ?
tadalafil - ertapenem - aptomycin - ganciclovir - efavirenz + emtricitabine + tenofovir - zoledronic acid 5 mg.
Both studies demonstrated statistical non-inferiority of eravacycline to two widely used comparators - ertapenem in IGNITE1 and meropenem in IGNITE4 - for the primary efficacy endpoint of clinical response at the test-of-cure visit.
CRKP was defined as an isolate with ertapenem (MICs ≥2 [micro]g/ml), or imipenem and/or meropenem (MICs ≥4 [micro]g/ml).
In Brazil, the following antimicrobials are considered acceptable for use in OPAT: amikacin, gentamicin, ceftriaxone, cefepime, ceftazidime, ceftaroline, ertapenem, linezolid (when formulation for oral use is not available), tigecycline, daptomycin, teicoplanin, vancomycin, amphotericin B (lipid formulations), caspofungin, anidulafungin, micafungin and voriconazole (when formulation for oral use is not available).
susceptible Escherichia Klebsiella Salmonella coli, pneumoniae, enterica, n = 20 n = 7 n = 6 Ampicillin 2 (10) 0 6 (100) Amoxicillin/ 5 (25) 1 (14) 6 (100) clavulanic acid Piperacillin/ 13 (65) 2 (29) 6 (100) tazobactam Cefuroxime 5 (25) 1 (14) NT Ceftriaxone 6 (30) 1 (14) 6 (100) Ceftazidime 6 (30) 1 (14) 6 (100) Cefipime 7 (35) 1 (14) 6 (100) Cefoxitin 11 (55) 4 (57) NT Aztreonam 6 (30) 1 (14) 6 (100) Ertapenem 17 (85) 4 (57) 6 (100) Imipenem 17 (85) 4 (57) 6 (100) Meropenem 17 (85) 4 (57) 6 (100) Gentamicin 14 (70) 2 (29) NT Tobramycin 9 (45) 1 (14) NT Ciprofloxacin 1 (5) 1 (14) 3 (43) Chloramphenicol 11 (55) 2 (29) 6 (100) Colistinf 20 (100) 7 (100) 6 (100) Nitrofurantoin 16 (80) 1 (14) NT Trimethoprim/ 2 (10) 2 (29) 6 (100) sulfamethoxazole Agent Organism, no.
Resistance to amikacin, cefotaxime, ertapenem, meropenem, cefuroxime, levofloxacin, netilmicin, gentamicin and ceftazidime was 100.
It showed intermediate susceptibility to imipenem and meropenem, resistance to ertapenem, and sensitivity only to colistin, amikacin, and trimethoprim-sulfamethoxazole.
Biopharmaceutical company Tetraphase Pharmaceuticals Inc (NasdaqGS:TTPH) reported on Tuesday the start of treatment of the first patient under its IGNITE3 phase 3 clinical trial of once-daily intravenous (IV) eravacycline compared to ertapenem in complicated urinary tract infections (cUTI).
Introduction: The primary aim of this study was to evaluate whether there was a difference between Outpatient paranteral antibiotic therapy (OPAT) and inpatient parenteral antibiotic therapy (IPAT) costs of ertapenem for urinary tract infections (UTI's) due to extended-spectrum beta-lactamase (ESBL) producing gram negative bacilli, and to discuss suitability of ertapenem for OPAT programme of Turkey for the near future.
The aim of this study was to assess the efficacy of the ertapenem loaded articulating spacers in two-stage revision for polymicrobial TKA infection.